Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis.

ABSTRACT: For over two years, the world has been facing the epidemiological and health challenge of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Growing problems are also complications after the development of COVID-19 in the form of post and long- COVID syndromes, posing a challenge for the medical community, both for clinicians and the scientific world. SARS-CoV-2 infection is associated with an increased risk of cardiovascular complications, especially thromboembolic complications, which are associated with both thrombosis of small and very small vessels due to immunothrombosis, and the development of venous thromboembolism. Low molecular wight heparin (LMHW) are the basic agents used in the prevention and

SUBMITTER: Dybowska M 

PROVIDER: S-EPMC9499629 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature